# CC100: Safety and Tolerability of Single Doses

> **NCT02050334** · PHASE1 · COMPLETED · sponsor: **Chemigen, LLC** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CC100
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02050334
- **Lead sponsor:** Chemigen, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-07
- **Final completion:** 2015-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02050334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02050334, "CC100: Safety and Tolerability of Single Doses". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02050334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*